Raymond James Analysts Give ZIOPHARM Oncology (NASDAQ:ZIOP) a $6.50 Price Target

ZIOPHARM Oncology (NASDAQ:ZIOP) received a $6.50 price objective from stock analysts at Raymond James in a research note issued to investors on Friday, BayStreet.CA reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Raymond James’ target price indicates a potential upside of 51.87% from the company’s current price.

ZIOP has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $6.50 target price on shares of ZIOPHARM Oncology in a research report on Wednesday, October 2nd. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Saturday, October 12th. ValuEngine downgraded shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, October 29th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $6.25.

Shares of NASDAQ ZIOP traded down $0.01 during midday trading on Friday, hitting $4.28. The company had a trading volume of 66,267 shares, compared to its average volume of 1,321,618. The company has a quick ratio of 6.33, a current ratio of 6.33 and a debt-to-equity ratio of 0.01. ZIOPHARM Oncology has a twelve month low of $1.56 and a twelve month high of $7.25. The business has a 50-day simple moving average of $4.23 and a two-hundred day simple moving average of $4.88. The firm has a market capitalization of $794.72 million, a price-to-earnings ratio of -8.90 and a beta of 2.60.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.34). On average, equities analysts forecast that ZIOPHARM Oncology will post -0.36 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its position in shares of ZIOPHARM Oncology by 0.3% during the second quarter. PNC Financial Services Group Inc. now owns 118,038 shares of the biotechnology company’s stock worth $648,000 after acquiring an additional 398 shares during the last quarter. Commonwealth Equity Services Inc grew its position in shares of ZIOPHARM Oncology by 1.6% during the second quarter. Commonwealth Equity Services Inc now owns 47,333 shares of the biotechnology company’s stock worth $260,000 after acquiring an additional 758 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of ZIOPHARM Oncology by 4.8% during the second quarter. Oppenheimer & Co. Inc. now owns 20,100 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 919 shares during the last quarter. Royal Bank of Canada grew its position in shares of ZIOPHARM Oncology by 6.4% during the first quarter. Royal Bank of Canada now owns 16,189 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 974 shares during the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of ZIOPHARM Oncology by 7.5% during the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 1,673 shares during the last quarter. Hedge funds and other institutional investors own 38.78% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

See Also: What is a dividend reinvestment plan?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply